Drug Trial Radar · NCT02570321
Cross-linking for Corneal Ulcers Treatment Trial
Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Nov 2015
Primary completion
Jun 18, 2018
Study completion Mar 19, 2019
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aravind Eye Hospitals, India
- First posted
- Oct 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine if patients randomized to corneal collagen cross-linking plus medical therapy will have a lower prevalence of positive bacterial or fungal cultures immediately after the procedure than patients who received medical therapy alone. The secondary purpose of this study is to determine if patients randomized to corneal collagen cross-linking will have a better visual acuity at 3 and 12 months than patients who receive medical therapy alone.
Conditions
- Corneal Ulcer
- Infectious Keratitis
- Bacterial Ulcer
- Fungal Ulcer
Interventions
Corneal Cross-linkingProcedure
For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
Anti Fungal DrugDrug
Topical Amphotericin B vs Topical Natamycin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microbiological Cure on Repeat CultureTime frame: 4 to 24 hours after enrollment
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Proctor Foundation, UCSF
San Francisco, California
Aravind Eye Hospitals
Madurai, Tamil Nadu, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.